Neuravi

Neuravi is an Irish medical device company based in Galway, established in 2009. The company specializes in neurointerventional therapies aimed at treating acute ischemic strokes. Neuravi develops advanced devices designed to remove blood clots from brain vessels, which helps restore blood flow and improve patient outcomes. The flagship product, the EmboTrap Revascularization Device, is a proprietary dual-layer stent-like system that efficiently captures and removes clots causing ischemic strokes. This device has been used to treat over 3,000 patients in Europe and is currently undergoing clinical trials in the U.S. to support FDA approval. Neuravi's focus on innovative solutions addresses a critical medical need, as strokes are a leading cause of death and disability worldwide. Founded by Eamon, David Vale, and John O'Shaughnessy, Neuravi received early investment from the Western Development Commission and EQT Life Sciences. In 2017, the company was acquired by Codman Neuro, a subsidiary of Johnson & Johnson, which has helped expand its reach in stroke treatment technology. Neuravi primarily serves hospitals and healthcare providers specializing in neurointerventional care.

• Employees 2
• Founded 2009
• Annual Revenue $2500000
• Total Funding $44549860